Table 1.

Vaccine‐induced humoral immune responses against different influenza A(H1N1)pnd09 viral strains.

	California/7/09	Finland/634/09	Finland/686/09	Finland/694/09	Finland6/10	Finland/19/10	Finland/20/10
Geometric mean titer [95% CI]
Pandemic vaccine*
Day 0 (n = 24)	5·3 [4·9–5·7]	5·8 [5·0–6·7]	5·6 [4·9–6·4]	5·0 [5·0–5·0]	5·8 [5·0–6·7]	5·8 [4·9–6·8]	6·7 [5·4–8·3]
Day 21 (n = 88)	65·2 [48·7–87·3]	82·6 [58·4–116·7]	57·5 [40·9–80·7]	9·8 [8·3–11·6]	38·2 [27·0–53·8]	43·6 [32·0–59·4]	107·9 [75·8–153·6]
Day 90 (n = 80**)	31·1 [23·5–41·2]	39·0 [28·0–54·2]	31·7 [23·4–42·9]	7·8 [6·6–9·2]	21·8 [15·8–30·1]	23·0 [17·4–30·4]	60·6 [43·9–83·7]
Seasonal vaccine***
Day 365 (n = 80) 80	20·9 [16·2–26·9]	29·5 [22·3–39·2]	22·2 [17·2–28·6]	7·5 [6·4–8·8]	16·8 [13·1–21·7]	19·5 [15·1–25·2]	38·0 [28·3–50·9]
Day 21 (n = 70)	127·4 [96·7–167·9]	187·5 [142·4–246·9]	150·8 [114·2–199·0]	32·2 [24·8–41·7]	106·6 [80·6–141·0]	139·3 [104·4–185·8]	307·6 [236·0–400·9]
Day 90 (n = 66)	74·3 [56·2–98·3]	108·5 [81·7–144·0]	87·0 [65·9–114·8]	18·8 [14·8–23·8]	60·9 [45·8–80·9]	72·0 [53·8–96·5]	165·1 [124·2–219·6]
Seroprotection rate†
Pandemic vaccine
Day 0	0·0	0·0	0·0	0·0	0·0	0·0	4·2
Day 21	69·3	71·6	62·5	13·6	50·0	56·8	75·0
Day 90	51·3	53·8	50·0	6·3	42·5	41·3	66·3
Seasonal vaccine
Day 365	33·8	50·0	38·8	5·0	32·5	33·8	56·3
Day 21	87·1	94·3	90·0	57·1	84·3	90·0	98·6
Day 90	80·3	87·9	81·8	28·8	75·8	75·8	93·9

^*One dose (3·75 μg HA) of AS03‐adjuvanted Pandemrix^TM vaccine produced by GSK Biologicals was given to healthy adults.

^**On day 90, thirteen individuals were given a second dose of Pandemrix^TM vaccine, these are included in the analysis.

^***One dose of non‐adjuvanted trivalent seasonal influenza vaccine Fluarix^TM produced by GSK Biologicals was given 1 year after the pandemic vaccination.

^†Seroprotection rate: the percentage of subjects who have a post‐vaccination titer ≥1:40.